000			02324nam a2200505 i 4500
999			_c287252 _d287252
001			on1112074275
003			OCoLC
005			20191004144724.0
006			m o d f
007			cr bn|||||||||
008			190812s2019 dcu o f000 0 eng c
040			_aPUCPR _beng _erda _epn _cGPO _dGPO _dMvI
042			_apcc
043			_an-us---
074			_a1016-C (online)
086	0		_aY 4.OV 2:116-24
088			_aSerial no. 116-24 (United States. Congress. House. Committee on Oversight and Reform)
099			_aY 4.OV 2:116-24
110	1		_aUnited States. _bCongress. _bHouse. _bCommittee on Oversight and Reform,
245	1	0	_aHIV prevention drug : _bbillions in corporate profits after millions in taxpayer investments : hearing before the Committee on Oversight and Reform, House of Representatives, One Hundred Sixteenth Congress, first session, May 16, 2019.
246	3		_aHuman Immunodeficiency Virus prevention drug
246	3	0	_aBillions in corporate profits after millions in taxpayer investments
264		1	_aWashington : _bU.S. Government Publishing Office, _c2019.
300			_a1 online resource (iii, 63 pages)
336			_btxt
337			_bc _2rdamedia
338			_bcr _2rdacarrier
500			_a"Serial no. 116-24."
500			_aCRDP Program record.
588			_aDescription based on online resource; title from PDF title page (govinfo, viewed Aug. 12, 2019).
776	0	8	_iPrint version: _aUnited States. Congress. House. Committee on Oversight and Reform. _tHIV prevention drug _w(OCoLC)1112356798
856	4	0	_3PDF version _uhttps://purl.fdlp.gov/GPO/gpo124188
856	4	0	_3Text version _uhttps://purl.fdlp.gov/GPO/gpo124189
050		4	_aKF27 _b.O96 2019i
610	2	0	_aGilead Sciences (Firm)
650		0	_aPre-exposure prophylaxis _xPrices _zUnited States.
650		0	_aPre-exposure prophylaxis _zUnited States _xCost control.
650		0	_aHIV infections _zUnited States _xPrevention.
650		0	_aPrescription pricing _xGovernment policy _zUnited States.
650		0	_aPharmaceutical industry _xPrices _xGovernment policy _zUnited States.
650		0	_aMedical policy _zUnited States.
650		0	_aFederal aid to medical research _zUnited States.
655		7	_aLegislative hearings. _2lcgft
942			_2sudocs _c8